دورية أكاديمية
Cannabinoids biology: the search for new therapeutic targets.
| العنوان: | Cannabinoids biology: the search for new therapeutic targets. |
|---|---|
| المؤلفون: | Felder CC; Eli Lilly and Co., Neuroscience Division, Indianapolis, IN 46285, USA., Dickason-Chesterfield AK, Moore SA |
| المصدر: | Molecular interventions [Mol Interv] 2006 Jun; Vol. 6 (3), pp. 149-61. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Society for Pharmacology and Experimental Therapeutics Country of Publication: United States NLM ID: 101093789 Publication Model: Print Cited Medium: Print ISSN: 1534-0384 (Print) Linking ISSN: 15340384 NLM ISO Abbreviation: Mol Interv Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Bethesda, MD : American Society for Pharmacology and Experimental Therapeutics, [2001]- |
| مواضيع طبية MeSH: | Cannabinoids/*metabolism , Cannabinoids/*therapeutic use, Animals ; Arachidonic Acids/metabolism ; Arachidonic Acids/pharmacology ; Biological Transport ; Cannabinoid Receptor Modulators/metabolism ; Cannabinoid Receptor Modulators/therapeutic use ; Cannabinoids/chemistry ; Cannabinoids/pharmacology ; Endocannabinoids ; Humans ; Polyunsaturated Alkamides/metabolism ; Polyunsaturated Alkamides/pharmacology ; Receptors, Cannabinoid/metabolism |
| مستخلص: | Cannabinoids, in the form of marijuana plant extracts, have been used for thousands of years for a wide variety of medical conditions, ranging from general malaise and mood disorders to more specific ailments, such as pain, nausea, and muscle spasms. The discovery of tetrahydrocannabinol, the active principal in marijuana, and the identification and cloning of two cannabinoid receptors (i.e., CB1 and CB2) has subsequently led to biomedical appreciation for a family of endocannabinoid lipid transmitters. The biosynthesis and catabolism of the endocannabinoids and growing knowledge of their broad physiological roles are providing insight into potentially novel therapeutic targets. Compounds directed at one or more of these targets may allow for cannabinoid-based therapeutics with limited side effects and abuse liability. |
| Number of References: | 141 |
| المشرفين على المادة: | 0 (Arachidonic Acids) 0 (Cannabinoid Receptor Modulators) 0 (Cannabinoids) 0 (Endocannabinoids) 0 (Polyunsaturated Alkamides) 0 (Receptors, Cannabinoid) UR5G69TJKH (anandamide) |
| تواريخ الأحداث: | Date Created: 20060701 Date Completed: 20070622 Latest Revision: 20161124 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1124/mi.6.3.6 |
| PMID: | 16809476 |
| قاعدة البيانات: | MEDLINE |
كن أول من يترك تعليقا!